Our goal is to be the leading biopharmaceutical company developing and marketing therapies that restore function and improve the lives of people with neurological disorders.

Acorda’s R&D efforts are designed to:

  • Develop CVT-301 as a potential treatment for OFF in people with Parkinson’s disease
  • Assess the potential of PLUMIAZ as a treatment for people with epilepsy who experience seizure clusters
  • Determine if dalfampridine is a therapeutic option for people with post-stroke walking deficits
  • Advance clinical development of rHIgM22, a remyelinating antibody, as a potential treatment for people with MS
  • Advance CVT-427 as a potential treatment for acute migraine
Click on a compound in development for more information.
Therapy Indication Phase 1 Phase 2 Phase 3
CVT-301
Parkinson's Disease
 
 
 
PLUMIAZ™ (diazepam) Nasal Spray
Seizure Clusters
 
 
 
DALFAMPRIDINE
Chronic Post-Stroke Walking Deficits
 
 
 
CVT-427
Migraine
 
 
 
rHlgM22
MS